Stroke Center Header
home research mission programs contact

Q: Who is eligible to be a study participant?
A: Individuals may be included in the study if they:
  • had a left hemisphere occlusive stroke in the past 30 to 92 days
  • have speech and language problems (aphasia)
  • are between 18 and 80 years old
Q: What is the process for participating?
A: The process includes:
  • Referral by self, family, physician or other allied health professional
  • Explanation of study and obtain consent to participate
  • Confirmation from primary care physician that participation is in personís best interest
  • Medical records review
  • Speech-language assessment
  • Confirmation that person meets study guidelines for participation
  • Schedule treatment:
    • Four days per week for six weeks
    • 1½ hours speech therapy daily
    • Dexedrine or placebo taken 30 minutes prior to two therapy sessions per week
    • Aricept or placebo taken daily for six weeks
  • Additional assessments will be completed after after 6 weeks of therapy and at 6 months from the date of beginning the study.
Q: Who do I contact to participate?
A: You may contact Sandra Curtis, the Stroke Center-Dallas Research Coordinator by phone at 214-689-6709 or by e-mail at strokecenter@twu.edu

You may also download, print, and complete the application form, and fax it to 214-689-6614. Download the application here. (You will need Adobe Acrobat to view and print the application. You can download it here).


Q: Where is the study conducted?
A: The Stroke Center-Dallas, at Texas Woman's University- Parkland Campus. It is conveniently located off I-35 E at 1810 Inwood Road, Dallas, TX 75235, as part of the medical center complex.

Q: When does it start?
A: Participants may begin treatment from 30 - 92 days after stroke. They must be medically stable and have the stamina to participate in 1.5 hours of speech/language treatment four days per week.

Q: How much does it cost?
A: There is no charge for any research-related assessment and drug-treatment sessions. For those people who live outside the Dallas-Fort Worth metroplex who choose to participate, there are residential hotel accommodations located nearby. All living expenses would be at the participantís own expense.

Q: Will I be paid for participation?
A: There is no direct payment for participating in this study. However, limited travel compensation is available for those who must travel some distance.

Q: What benefits can be expected from participating in the study?
A: There are no guaranteed benefits from participating in this study. Possible benefits might include an increase in the rate and total amount of recovery of language functions. All participants receive 36 hours of speech therapy at no cost. Participants may be eligible for long-term treatment or LifeLink programs at The Stroke Center-Dallas.

Q: How does participation benefit stroke research?
A: The participantsí response to the drug-therapy regime will help researchers to determine if this is to become a standard of care for treating other individuals with similar problems as a result of stroke.

Q: What are the research findings thus far?
A: The findings of our pilot study suggest that a drug combination of amphetamine & donepezil, when paired with relevant behavioral therapy, enhances the rate of recovery from aphasia (Walker-Batson, et al., 1995) that is greater than our previous study of amphetamine alone (Walker-Batson et al., 2001) The safety study of the drug combination showed no negative side effects.

Q: Is there additional published information regarding this study?
A: Click on the links below to read these important peer-reviewed publications:
  • (1) Walker-Batson, D, Smith, P, Curtis, S. Unwin, H, Greenlee, R. (1995).
    Amphetamine paired with physical therapy accelerates motor recovery following stroke: Further evidence. Stroke; 26:2254-2259 (download .pdf)


  • (2) Unwin, H. and Walker-Batson, D. (2000).
    No side effects after low-dose amphetamine administration in stroke rehabilitation. Stroke; 31:1788-1789 (download .pdf)


  • (3) Walker-Batson, D., Curtis, S. Natarajan, R, Ford, J. Dronkers, N, Salmeron, E, Lai, J, & Unwin, DH. (2001).
    A double-blind placebo controlled study of the use of amphetamine in the treatment of aphasia. Stroke; 32:2093-2098 (download .pdf)


  • (4) Walker-Batson, D., Smith, P., Curtis, S. and Unwin, D.H. (2004).
    Neuromodulation paired with learning dependent practice to enhance post stroke recovery? Restorative Neurology and Neuroscience; 22:387-392(download .pdf)

    (Note: You will need Adobe Acrobat to view these documents. You can download it here).


return to Research Page



Home   |   Research   |   Mission   |   Programs   |   Contact